About Ret finger protein-like 2
Ret finger protein-like 2 (RFPL2) is a protein
from Homo sapiens identified by UniProt accession
O75678, 378 residues long.
MolForge cross-references it against 0 known binders and
21 disease associations.
Target properties
| Protein name | Ret finger protein-like 2 |
| UniProt accession | O75678 |
| Gene | RFPL2 |
| Organism | Homo sapiens |
| Length | 378 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (21)
Diseases linked to this target (Open Targets).
- docosahexaenoic acid measurement · score 0.09
- visual perception measurement · score 0.07
- HbA1c measurement · score 0.05
- anti-chlamydia trachomatis antibody measurement · score 0.04
- urate measurement · score 0.04
- type 2 diabetes mellitus · score 0.04
- glucose tolerance test · score 0.03
- glucagon-like peptide-1 measurement · score 0.03
- 1,5 anhydroglucitol measurement · score 0.03
- hemoglobin A1 measurement · score 0.03
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-O75678-F1 | alphafold | PREDICTED | 73.41 | — |
Amino-acid sequence (378 residues)
MEVAELGFPE TAVSQSRICL CAVLCGHWDF ADMMVIRSLS LIRLEGVEGR DPVGGGNLTN KRPSCAPSPQ DLSAQWKQLE DRGASSRRVD MAALFQEASS CPVCSDYLEK PMSLECGCAV CLKCINSLQK EPHGEDLLCC CSSMVSRKNK IRRNRQLERL ASHIKELEPK LKKILQMNPR MRKFQVDMTL DANTANNFLL ISDDLRSVRS GRIRQNRQDL AERFDVSVCI LGSPRFTCGR HCWEVDVGTS TEWDLGVCRE SVHRKGRIQL TTELGFWTVS LRDGGRLSAT TVPLTFLFVD RKLQRVGIFL DMGMQNVSFF DAESGSHVYT FRSVSAEEPL RPFLAPSVPP NGDQGVLSIC PLMNSGTTDA PVRPGEAK
Explore Ret finger protein-like 2 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets